Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RE-Enable
- Development stage
- Unknown
- Lead developer
- Re-Stem Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
RE-Enable is an autologous cell therapy developed by Re-Stem Biotech specifically for the treatment of spinal cord injury (SCI). As an autologous treatment, it utilizes the patient's own cells, which are processed and re-administered to promote neural repair, reduce inflammation, and support functional recovery at the site of spinal damage. The therapy is designed to address the complex pathophysiology of SCI by leveraging the regenerative potential of stem cells to restore motor and sensory functions. It is currently in Phase 1/2 clinical development, focusing on safety and preliminary efficacy in patients with spinal cord damage.
- Brand names
- RE-Enable
Beyond the preview
Go deeper on RE-Enable.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RE-Enable.